These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 17979772)

  • 1. SPR-based fragment screening: advantages and applications.
    Neumann T; Junker HD; Schmidt K; Sekul R
    Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
    Giannetti AM
    Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment screening by SPR and advanced application to GPCRs.
    Shepherd CA; Hopkins AL; Navratilova I
    Prog Biophys Mol Biol; 2014; 116(2-3):113-23. PubMed ID: 25301577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental validation of a fragment library for lead discovery using SPR biosensor technology.
    Elinder M; Geitmann M; Gossas T; Källblad P; Winquist J; Nordström H; Hämäläinen M; Danielson UH
    J Biomol Screen; 2011 Jan; 16(1):15-25. PubMed ID: 21149860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplexed experimental strategies for fragment library screening against challenging drug targets using SPR biosensors.
    FitzGerald EA; Vagrys D; Opassi G; Klein HF; Hamilton DJ; Talibov VO; Abramsson M; Moberg A; Lindgren MT; Holmgren C; Davis B; O'Brien P; Wijtmans M; Hubbard RE; de Esch IJP; Danielson UH
    SLAS Discov; 2024 Jan; 29(1):40-51. PubMed ID: 37714432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
    Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
    J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experiences in fragment-based lead discovery.
    Hubbard RE; Murray JB
    Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment library screening and lead characterization using SPR biosensors.
    Danielson UH
    Curr Top Med Chem; 2009; 9(18):1725-35. PubMed ID: 19929838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment screening for drug leads by weak affinity chromatography (WAC-MS).
    Ohlson S; Duong-Thi MD
    Methods; 2018 Aug; 146():26-38. PubMed ID: 29378316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?
    Wielens J; Headey SJ; Rhodes DI; Mulder RJ; Dolezal O; Deadman JJ; Newman J; Chalmers DK; Parker MW; Peat TS; Scanlon MJ
    J Biomol Screen; 2013 Feb; 18(2):147-59. PubMed ID: 23139382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Label free fragment screening using surface plasmon resonance as a tool for fragment finding - analyzing parkin, a difficult CNS target.
    Regnström K; Yan J; Nguyen L; Callaway K; Yang Y; Diep L; Xing W; Adhikari A; Beroza P; Hom RK; Riley B; Rudolph D; Jobling MF; Baker J; Johnston J; Konradi A; Bova MP; Artis DR
    PLoS One; 2013; 8(7):e66879. PubMed ID: 23861750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process.
    Danielson UH
    Future Med Chem; 2009 Nov; 1(8):1399-414. PubMed ID: 21426056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fragment screening using surface plasmon resonance optical biosensor technology].
    Miura T
    Yakugaku Zasshi; 2010 Mar; 130(3):341-8. PubMed ID: 20190519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosensor-surface plasmon resonance: A strategy to help establish a new generation RNA-specific small molecules.
    Vo T; Paul A; Kumar A; Boykin DW; Wilson WD
    Methods; 2019 Sep; 167():15-27. PubMed ID: 31077819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels.
    Hämäläinen MD; Zhukov A; Ivarsson M; Fex T; Gottfries J; Karlsson R; Björsne M
    J Biomol Screen; 2008 Mar; 13(3):202-9. PubMed ID: 18270366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developments in SPR Fragment Screening.
    Chavanieu A; Pugnière M
    Expert Opin Drug Discov; 2016; 11(5):489-99. PubMed ID: 26948323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Guide to Run Affinity Screens Using Differential Scanning Fluorimetry and Surface Plasmon Resonance Assays.
    Bergsdorf C; Wright SK
    Methods Enzymol; 2018; 610():135-165. PubMed ID: 30390797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Label-enhanced surface plasmon resonance applied to label-free interaction analysis of small molecules and fragments.
    Eng L; Nygren-Babol L; Hanning A
    Anal Biochem; 2016 Oct; 510():79-87. PubMed ID: 27325502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis.
    Olaru A; Bala C; Jaffrezic-Renault N; Aboul-Enein HY
    Crit Rev Anal Chem; 2015; 45(2):97-105. PubMed ID: 25558771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.